Navigation Links
Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
Date:4/24/2008

- Full Results Presented at European Association for the Study of the Liver

Annual Meeting -

SAN FRANCISCO, April 24 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today, at the European Meeting for the Study of the Liver (EASL), the positive results of a Phase 2 trial of its lead compound MitoQ(R) (mitoquinone) in liver disease. The trial, conducted by Dr. Edward Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, successfully met the primary clinical endpoint, the reduction of elevated liver enzymes.

In the 28-day trial, 30 patients with the Hepatitis C virus (HCV) were enrolled to study the effects of MitoQ on elevated liver enzymes. Researchers measured patients' baseline levels of aminotransferase (ALT), an enzyme released into the blood that indicates damage to the liver. The double-blind trial randomized patients to one of three treatment groups: MitoQ 40mg/day, MitoQ(R) 80mg/day or placebo. The primary endpoint was the reduction of levels of ALT. Patients who received MitoQ showed a significant decrease in ALT levels at the end of the study compared with baseline levels. The decrease from baseline was 26.4% (p<0.002) for patients in the 40mg dose group, and 28% (p<0.05) for patients in the 80mg dose group. These results suggest that MitoQ can reduce necroinflammation and may halt disease progression to fibrosis or cirrhosis.

The drug was well tolerated with no significant safety issues. Commonly reported adverse events (AEs) included nausea, headache and vomiting, which were usually mild and well tolerated. Only one patient withdrew from the study due to nausea. There were no significant laboratory or ECG abnormalities observed and no serious adverse events (SAEs) were reported.

"In patients with chronic liver disease, including the two patient populations with the largest unmet need -- patients with chronic hepatitis C, who have failed
'/>"/>

SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
2. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
4. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
5. Amylin Pharmaceuticals Reports First Quarter Financial Results
6. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
7. Access Pharmaceuticals Announces New Data on Angiolix(R)
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
11. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... May 25, 2013 For college ... finals week. Increasingly, they are turning to prescription ... and study. For more on this, go to ... treatment facility, warns that students who pick up ... at risk for developing a physical and psychological ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... 2013 The current residents of Back2Basics - ... the B2B staff all came together Saturday, May 18th to ... of Indian Cuisine, the residents got up to thank Roy ... on their road to recovery, and giving them a second ... center in 2010 after realizing the need for a long-term ...
(Date:5/25/2013)... 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html , ... judge's overturning of a jury's award of $6.5 million ... trial* in the country over allegations that the diabetes ... files. , The judge in the case ruled that ... his cancer was caused by the medication.** , Bloomberg ...
(Date:5/25/2013)... 2013 AdvantaClean of Pikes Peak recently ... for a healthy home and business in Colorado Springs ... , mold inspections, mold testing, mold removal , ... coil cleaning. , With over 120 offices nationwide, AdvantaClean ... offering a full suite of services for commercial, institutional, ...
Breaking Medicine News(10 mins):Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 3Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 4
... diabetes found in mice could open the door to exploring ... System research has found. Drugs for type 2 diabetes ... U-M study suggests that glucagon a pancreas-produced hormone that ... levels may also provide a powerful pathway to preventing ...
... editors of Gastroenterology , the official journal of ... announce the publication of this year,s highly anticipated special ... devoted to a particular gastroenterological topic of broad interest; ... conjunction with editor-in-chief M. Bishr Omary, MD, PhD, this ...
... Maureen Salamon HealthDay Reporter , MONDAY, May 14 ... often played for drama or laughs, but the phenomenon is ... In what they said is the first research in ... from Stanford University School of Medicine found that about 3.6 ...
... A new national initiative promises to improve college biology ... change how post-secondary life sciences departments approach education. ... Education, is a collaborative effort funded by the National ... the Howard Hughes Medical Institute (HHMI). Program organizers ...
... ,Communities of Solution, to Address Today,s Fragmented U.S. Health ... to reform the U.S. health care system, a group ... of community-centered health systems, as originally outlined in the ... the original Folsom commission could not be more pertinent ...
... MONDAY, May 14 (HealthDay News) -- People with HIV/AIDS are ... than those in the general population, a new study finds. ... HIV, according to researchers from the University of California, San ... sudden cardiac death, the heart suddenly and unexpectedly stops beating. ...
Cached Medicine News:Health News:New inflammation hormone link may pave way to study new drugs for Type 2 diabetes 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 3Health News:Sleepwalking in Adults More Common Than Thought 2Health News:Sleepwalking in Adults More Common Than Thought 3Health News:National initiative launched to change the way biology departments approach undergraduate education 2Health News:National initiative launched to change the way biology departments approach undergraduate education 3Health News:May/June 2012 Annals of Family Medicine tip sheet 2Health News:May/June 2012 Annals of Family Medicine tip sheet 3Health News:May/June 2012 Annals of Family Medicine tip sheet 4Health News:May/June 2012 Annals of Family Medicine tip sheet 5Health News:May/June 2012 Annals of Family Medicine tip sheet 6Health News:May/June 2012 Annals of Family Medicine tip sheet 7Health News:May/June 2012 Annals of Family Medicine tip sheet 8Health News:People With HIV at Higher Odds of Sudden Cardiac Death 2
(Date:5/24/2013)... Solta Medical, Inc. (NASDAQ: SLTM ), ... Dr. Edward W. Knowlton has resigned ... immediately.  Dr. Knowlton is the founder of Thermage, the predecessor ... since 1996. "On behalf of the entire Board ... like to thank Ed for his tireless dedication to our ...
(Date:5/24/2013)... , May 24, 2013 In accordance with ... and Rule 14e-1 of the United States Exchange Act, Echo ... original offer for Elan Corporation (NYSE: ELN). Background ... ("Royalty Pharma") made an offer for the entire of the ... plc ("Elan") (the "Original Offer").  On 20 ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: